Shortly after his diagnosis, WIlliams was in and out of the hospital every two weeks throughout the fall, until the new year.

The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...

The range of autoimmune diseases treatable with chimeric antigen receptor (CAR) T-cell therapy could be much broader than ...

A Spanish trial finds similar sustained IBD clinical remission rates 1-year post-withdrawal vs maintenance of anti-TNF ...

The Food and Drug Administration (FDA) has expanded the approval of Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC) to include a ...

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s ...

The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately to severely ...

With a fresh endorsement from the FDA, Johnson & Johnson has rounded out Tremfya’s presence in inflammatory bowel disease ...

Risk for venous thromboembolism (VTE) after an operation for colorectal cancer (CRC) is higher among patients with inflammatory bowel disease (IBD), according to results of a population-based cohort ...

For decades, scientists have puzzled over why smoking makes Crohn’s disease worse but seems to protect people from ulcerative ...

Meanwhile, a systematic review and meta-analysis in Lancet Gastroenterology & Hepatology examined differences in risks for ...

Among patients with IBD, HLA-B27 positivity and higher UC disease activity were associated with an increased risk for SpA.